Vibliome Therapeutics

Vibliome Therapeutics has developed a new, systematic approach that enables the design of small molecule Type II kinase inhibitors with unique profiles and a high degree of selectivity

Year Established: 2017 Stock Ticker: Exchange:

Locations

  • Vibliome Therapeutics

     Bozeman MT

    Vibliome Therapeutics has developed a new, systematic approach that enables the design of small molecule Type II kinase inhibitors with unique profiles and a high degree of selectivity

  • Vibliome Therapeutics

     New York NY

    Vibliome Therapeutics has developed a new, systematic approach that enables the design of small molecule Type II kinase inhibitors with unique profiles and a high degree of selectivity